edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Mendus
Mendus is an immuno-oncology company focused on immunotherapies for myeloid blood cancers. The company’s leading clinical candidate is vididencel, an off-the-shelf cellular immunotherapy that has demonstrated durable clinical remissions in acute myeloid leukemia (AML). Mendus is developing vididencel as a broadly applicable post-remission treatment in AML and has expanded indications to include chronic myeloid leukemia (CML). Earlier-stage programs focusing on ovarian cancer and other solid tumors.
Mendus — 11 videos in collection
Immunicum is a clinical-stage immunoncology company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumours. Its lead clinical asset in development (Phase II, acute myeloid leukaemia) is based on intratumoural priming and cancer relapse vaccination.
In this video, the company’s chief executive officer, Erik Manting, provides an overview of the company’s strategy and differentiated approach.
Get access to the very latest content matched to your personal investment style.